Skip to main content
Equibles

RA CAPITAL MANAGEMENT, L.P.

Position in NTLA — Intellia Therapeutics, Inc.

CIK 1346824 BOSTON, MA
Back to NTLA Full portfolio

Position in NTLA

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$76,595,587
+$74,166,937 QoQ
Shares Held
4,526,926
+30079.5% QoQ
Ownership
3.23%
of shares outstanding
% of Portfolio
0.67%
of 13F equity value
Holder Rank
#9
of 330 holders
Holding Since
Jun 2021
2 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in NTLA Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

RA CAPITAL MANAGEMENT, L.P. holds $11,082,969,028 across 75 Biotechnology names. NTLA ranks #28 (0.7% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 ASND
Ascendis Pharma A/S
 10,281,496 $2,742,280,613
2 PBLS
Parabilis Medicines, Inc.
 28,933,371 $791,906,364
3 RYTM
Rhythm Pharmaceuticals, Inc.
 6,666,837 $740,218,912
4 PCVX
Vaxcyte, Inc.
 11,474,599 $667,018,439
5 SION
Sionna Therapeutics, Inc.
 9,905,045 $435,722,929
6 TYRA
Tyra Biosciences, Inc.
 12,198,625 $389,624,082
7 EWTX
Edgewise Therapeutics, Inc.
 8,392,730 $340,996,619
8 NAMS
NewAmsterdam Pharma Co N.V.
 9,883,524 $330,779,298

All Filings in NTLA

Export CSV
2 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $76,595,587 4,526,926
2021-06-30 $2,428,650 15,000